|
1
|
Barreira-Díaz A, Riveiro-Barciela M, Fernández-Bonilla EM, Bernal V, Castiella A, Casado-Martín M, Delgado C, Londoño MC, Díaz-González Á, Pérez-Medrano I, Conthe A, Sala M, Mateos B, Gómez-Camarero J, Antón-Conejero D, Pozo-Calzada CD, Cuenca F, Villagrasa-Vilella A, Salcedo M. Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study. Ann Hepatol 2024; 29:101489. [PMID: 38403068 DOI: 10.1016/j.aohep.2024.101489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/13/2023] [Accepted: 12/05/2023] [Indexed: 02/27/2024]
Abstract
INTRODUCTION AND OBJECTIVES Different patterns of liver injury have been reported in association with the SARS-CoV-2 vaccines. The aim of this study was to describe a nationwide cohort of patients with SARS CoV-2 vaccine-induced liver injury, focusing on treatment and the evolution after further booster administration. PATIENTS AND METHODS multicentre, retrospective-prospective study, including subjects who developed abnormal liver tests within 90 days after administration of SARS-CoV-2 vaccination. RESULTS 47 cases were collected: 17 after prime dose and 30 after booster. Age was 57 years, 30 (63.8 %) were female, and 7 (14.9 %) had a history of prior autoimmune hepatitis (AIH). Most cases were non-severe, though 9 (19.1 %) developed acute liver injury or failure (ALF). Liver injury tended to be more severe in those presenting after a booster (p=0.084). Pattern of liver injury was hepatocellular (80.9 %), mixed (12.8 %) and 3 (6.4 %) cholestatic. Liver biopsy was performed on 33 patients; 29 showed findings of AIH. Forty-one (87.2 %) patients received immunosuppressants, mostly corticosteroids (35/41). One required liver transplantation and another died due to ALF. Immunosuppression was discontinued in 6/41 patients without later rebound. Twenty-five subjects received at least one booster and 7 (28.0 %) relapsed from the liver injury, but all were non-severe. Recurrence was less frequent among patients on immunosuppressants at booster administration (28.6 % vs. 88.9 %, p=0.007). CONCLUSIONS SARS CoV-2 vaccine-induced liver injury is heterogeneous but mostly immune-mediated. Relapse of liver injury after re-exposure to vaccine is frequent (28.0 %) but mild. Immunosuppression at booster administration is associated with a lower risk of liver injury.
Collapse
Affiliation(s)
- Ana Barreira-Díaz
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Liver Unit, Hospital Universitario Vall de Hebrón, Barcelona, Spain
| | - Mar Riveiro-Barciela
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Universitario Vall de Hebrón, Barcelona, Spain.
| | | | - Vanesa Bernal
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | | | | | | | - María-Carlota Londoño
- Institut D'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Liver Unit, Hospital Clínic Barcelona, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Álvaro Díaz-González
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), Santander, Spain
| | - Indhira Pérez-Medrano
- Gastroenterology and Hepatology Department, Complejo Hospitalario Universitario de Pontevedra, Spain
| | - Andrés Conthe
- Hepatology and Liver Transplantation Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Margarita Sala
- Gastroenterology Department, Hospital Universitari Josep Trueta, Girona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Beatriz Mateos
- Digestive Department, Hospital Ramón y Cajal, Madrid, Spain
| | | | - Dolores Antón-Conejero
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Digestive Department, Hospital Universitario Dr. Peset, Valencia, Spain
| | | | - Francisca Cuenca
- Gastroenterology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - Ares Villagrasa-Vilella
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Liver Unit, Hospital Universitario Vall de Hebrón, Barcelona, Spain
| | - Magdalena Salcedo
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Hepatology and Liver Transplantation Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
|
2
|
Casas-Deza D, Bernal-Monterde V, Betoré-Glaria E, Julián-Gomara AB, Yagüe-Caballero C, Sanz-París A, Fernández-Bonilla EM, Fuentes-Olmo J, Arbones-Mainar JM. Liver Disease Undernutrition Screening Tool Questionnaire Predicts Decompensation and Mortality in Cirrhotic Outpatients with Portal Hypertension. Nutrients 2023; 15:3780. [PMID: 37686812 PMCID: PMC10489934 DOI: 10.3390/nu15173780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 08/23/2023] [Accepted: 08/28/2023] [Indexed: 09/10/2023] Open
Abstract
BACKGROUND Numerous scores are designed to predict outcomes of patients with liver cirrhosis. Our study aimed to evaluate the ability of the Liver Disease Undernutrition Screening Tool (LDUST) in predicting mortality and decompensation in outpatients with clinically significant portal hypertension (CSPH). We hypothesized that LDUST could help identify patients in need of nutritional supplementation and intervention. METHODS A prospective study of 57 CSPH patients (36.8% female, mean age: 63.5 ± 9.9 years) with a median follow-up of 41 months was conducted. Baseline liver function, nutrition, and sarcopenia were assessed, alongside LDUST. During follow-up, the occurrence of liver decompensation, hospital admission, need for emergency care, and mortality were evaluated. RESULTS A total of 56.1% of patients were Child A, and the most frequent etiology was alcohol (50.9%). Malnutrition risk according to LDUST raised mortality (HR: 25.96 (1.47-456.78)), decompensation (HR 9.78 (2.08-45.89)), and admission (HR 4.86 (1.09-21.61)) risks in multivariate Cox analysis. Combining LDUST with Child and MELD scores improved their decompensation prediction (0.936 vs. 0.811 and 0.866 vs. 0.700). CONCLUSIONS The LDUST has a solid ability to predict complications in cirrhosis outpatients with CSPH, and its integration with Child and MELD models enhances their predictive power. LDUST implementation could identify individuals necessitating early nutritional support.
Collapse
Affiliation(s)
- Diego Casas-Deza
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
| | - Vanesa Bernal-Monterde
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
| | - Elena Betoré-Glaria
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
| | - Ana Belén Julián-Gomara
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
| | - Carmen Yagüe-Caballero
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
| | - Alejandro Sanz-París
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
- Endocrinology and Nutrition Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain
| | - Eva María Fernández-Bonilla
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
| | - Javier Fuentes-Olmo
- Gastroenterology and Hepatology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (V.B.-M.); (E.B.-G.); (A.B.J.-G.); (C.Y.-C.); (E.M.F.-B.); (J.F.-O.)
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
| | - Jose M. Arbones-Mainar
- Instituto de Investigación Sanitaria de Aragón (IISA), 50009 Zaragoza, Spain; (A.S.-P.); (J.M.A.-M.)
- Instituto Aragonés de Ciencias de la Salud (IACS), 50009 Zaragoza, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CiberOBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| |
Collapse
|